Krystal Biotech (KRYS) Earnings Analysis

Krystal Biotech (KRYS) next reports earnings on 2026-08-03, consensus EPS 1.7 USD. Last quarter (2026-05-04) it beat with EPS 1.83 USD vs 1.45 USD est (+26.2%). It has beaten estimates in 7/7 recent quarters (100%). Trailing P/E 43.46.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does KRYS next report earnings?

Next earnings date2026-08-03
Consensus EPS estimate1.7 USD
Revenue estimate0.12B

KRYS earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-041.83 USD1.45 USD+26.2%Beat
2026-02-171.7 USD1.62 USD+4.9%Beat
2025-11-032.66 USD1.12 USD+137.5%Beat
2025-08-041.29 USD1.08 USD+19.4%Beat
2025-02-191.52 USD1.29 USD+17.8%Beat
2024-11-040.91 USD0.9 USD+1.1%Beat
2024-08-050.86 USD0.5 USD+72%Beat

Beat rate: 7/7 (100%) over reported quarters with consensus data.

KRYS valuation and analyst view

Trailing P/E43.46
Trailing EPS7.683 USD
Price / book7.73
Dividend yield0.00%
Market cap9.99B
Analyst consensusBuy (17 buy / 0 hold / 0 sell)
Avg price target378.33 USD

Related research pages

Frequently asked questions

When is Krystal Biotech (KRYS)'s next earnings date?

Krystal Biotech is next scheduled to report on 2026-08-03, with a consensus EPS estimate of 1.7 USD and revenue estimate of 0.12B.

Did KRYS beat earnings last quarter?

In its 2026-05-04 report, KRYS posted EPS of 1.83 USD versus a 1.45 USD estimate — a beat of 26.2%.

What is KRYS's earnings track record?

Over the last 7 reported quarters with consensus data, KRYS beat estimates 7 times (100%).

What is KRYS's current P/E ratio and EPS?

KRYS trades at a trailing P/E of 43.46 on trailing EPS of 7.683351543294182 USD.

What do analysts rate KRYS?

Analyst consensus is "Buy" across 17 ratings (0 strong buy, 17 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 378.33 USD.